{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:50Z","timestamp":1782337250699,"version":"3.54.5"},"reference-count":33,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved for marketing in chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). We report final, long-term phase 1\/2 study results in 99 patients with treatment-naive (TN) and 134 with relapsed\/refractory (R\/R) CLL\/SLL. At final data cutoff, 71% and 31% of patients in the TN and R\/R cohorts, respectively, remained on acalabrutinib treatment (median follow-up of 73.7 and 52.6 months). Among the events of clinical interest (any grade) in the TN and R\/R cohorts, atrial fibrillation was reported in 6.1% and 9.0%, hypertension in 29.3% and 23.1%, other malignancies (excluding nonmelanoma skin cancer) in 14.1% and 17.2%, and major bleeding in 8.1% and 8.2% of patients, respectively. The incidence of the most common adverse events decreased over time. Overall response rates were 97.0% and 94.8% in the TN and R\/R cohorts, respectively, with similar response findings among patients with standard and high-risk genomic features. In the TN cohort, median progression-free survival (PFS) was not reached and the 72-month PFS rate was 86.7% (95% confidence interval [CI], 77.0-92.5). For the R\/R cohort, median PFS was 66.1 months (range, 0.4-87.8) and the 72-month PFS rate was 45.1% (95% CI, 35.6-54.1). This final analysis extends the duration of benefit observed with acalabrutinib, demonstrates that no new safety signals are apparent with longer follow-up, and confirms the safety and tolerability of acalabrutinib monotherapy for patients with CLL\/SLL. This trial was registered at www.clinicaltrials.gov as #NCT02029443.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018310","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:30:26Z","timestamp":1774989026000},"page":"3931-3941","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Final phase 2 study results of acalabrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"10","author":[{"given":"Richard R.","family":"Furman","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"2Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-3034","authenticated-orcid":false,"given":"Piers E. M.","family":"Patten","sequence":"additional","affiliation":[{"name":"3School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King\u2019s College London, London, United Kingdom"},{"name":"4Department of Haematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge M.","family":"Chaves","sequence":"additional","affiliation":[{"name":"5Northwest Medical Specialties, Tacoma, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"6Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"7Department of Haematology, St James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"8Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"9Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"10Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"},{"name":"11Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"13Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"de Borja","sequence":"additional","affiliation":[{"name":"15AstraZeneca, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"16AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"2Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"17Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026060911314618000_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-019-0139-8","article-title":"Frontline therapies for untreated chronic lymphoid leukemia","volume":"8","author":"Liu","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2026060911314618000_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11899-021-00652-2","article-title":"Management of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma in the era of targeted therapies","volume":"17","author":"Rainone","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"2026060911314618000_bib3","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026060911314618000_bib4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026060911314618000_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026060911314618000_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"issue":"22","key":"2026060911314618000_bib7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"2026060911314618000_bib8","doi-asserted-by":"crossref","first-page":"103696","DOI":"10.1016\/j.critrevonc.2022.103696","article-title":"Ibrutinib-associated dermatologic toxicities: a systematic review and meta-analysis","volume":"174","author":"Nocco","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2026060911314618000_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.02.001","article-title":"Ibrutinib-associated arthralgias\/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes","volume":"20","author":"Rhodes","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026060911314618000_bib10","author":"Tivdak","year":"2024"},{"issue":"18","key":"2026060911314618000_bib11","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026060911314618000_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060911314618000_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2026060911314618000_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2026060911314618000_bib15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026060911314618000_bib16","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-na\u00efve chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2026060911314618000_bib17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2026060911314618000_bib18","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10232","key":"2026060911314618000_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"2026060911314618000_bib20","author":"Calquence","year":"2022"},{"issue":"12","key":"2026060911314618000_bib21","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"11","key":"2026060911314618000_bib22","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026060911314618000_bib23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2026060911314618000_bib24","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2026060911314618000_bib25","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026060911314618000_bib26","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"31","key":"2026060911314618000_bib27","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911314618000_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060911314618000_bib29","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2026060911314618000_bib30","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1002\/hon.70008","article-title":"Molecular profiling identifies CD49d and CD79b as predictive markers for acquired acalabrutinib resistance in patients with chronic lymphocytic leukemia","volume":"43","author":"Bibikova","year":"2025","journal-title":"Hematol Oncol"},{"issue":"13","key":"2026060911314618000_bib31","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026060911314618000_bib32","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"2026060911314618000_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3931\/2523615\/blooda_adv-2025-018310-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3931\/2523615\/blooda_adv-2025-018310-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:31:55Z","timestamp":1781019115000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3931\/567501\/Final-phase-2-study-results-of-acalabrutinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018310","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,28]]}}}